As expected, genetically predicted PCSK9 inhibition showed a significant association with reduced LDL-C and CAD risk, but no significant association with monocyte or platelet traits, indicating that the latter were likely to be independent of lipid-lowering effects of statins. The gene discussed is PCSK9; the disease is coronary artery disorder.